Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

NCT07505173 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases

Interventions

OTHER: Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O
DRUG: Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]
[object Object]